Pomalidomide and Obinutuzumab for Relapsed Indolent Lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a combination of two drugs—pomalidomide (a pill) and obinutuzumab (an infusion)—for adults whose indolent lymphoma has come back or stopped responding to previous treatment. The goal is to see if this combination works better and is safe for this type of lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older with a type of lymphoma called CD20-positive indolent lymphoma (like follicular, marginal zone, or small lymphocytic lymphoma).
- Your lymphoma must have come back or not responded after at least one prior treatment.
- You must be generally active and able to care for yourself (ECOG score 0-2).
- Your blood cell counts (white cells, neutrophils, platelets, and hemoglobin) must meet minimum levels, though some help from medications or transfusions is allowed.
- Your liver and kidney function must be adequate (specific blood test limits apply).
- You must not have had a blood clot or stroke, uncontrolled heart disease, or active infections like HIV or hepatitis B/C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a three-drug combination (pomalidomide, an anti-CD20 antibody, and prednisone) to treat certain slow-growing B-cell lymphomas that have never been treated before. The goal is to see if this combination works better than standard approaches.
This trial studies whether obinutuzumab combined with lenalidomide can control marginal zone lymphoma that has come back or not responded to prior treatment. If you qualify, you may receive these medicines together to help shrink tumors and improve symptoms.
This study tests whether a combination of two drugs (pomalidomide and rituximab) can help prevent lymphoma from coming back after initial treatment. It is for younger patients with high-risk DLBCL who responded well to their first therapy.
This study looks at giving obinutuzumab together with lenalidomide to adults whose follicular lymphoma has come back or did not respond well to prior treatment. It may help control the cancer after relapse or resistance to standard therapies.
This trial tests a combination of three drugs (pomalidomide, rituximab, and an immunotherapy called anti-PD-1) for people with diffuse large B-cell lymphoma that has not responded or has come back after two prior treatments. The goal is to see if this combination can help control the lymphoma.
This trial tests a combination of two drugs for people newly diagnosed with marginal zone lymphoma (MZL). The goal is to see if the combination works better than standard treatments.
Hear when a new Indolent Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.